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Neurodegeneration is a complex process involving different cell types and neurotransmitters. A common characteristic of
neurodegenerative disorders is the occurrence of a neuroinflammatory reaction in which cellular processes involving glial cells,
mainly microglia and astrocytes, are activated in response to neuronal death. Microglia do not constitute a unique cell population
but rather present a range of phenotypes closely related to the evolution of neurodegeneration. In a dynamic equilibrium with
the lesion microenvironment, microglia phenotypes cover from a proinflammatory activation state to a neurotrophic one directly
involved in cell repair and extracellular matrix remodeling. At each moment, the microglial phenotype is likely to depend on
the diversity of signals from the environment and of its response capacity. As a consequence, microglia present a high energy
demand, for which the mitochondria activity determines the microglia participation in the neurodegenerative process. As such,
modulation of microglia activity by controlling microglia mitochondrial activity constitutes an innovative approach to interfere
in the neurodegenerative process. In this review, we discuss the mitochondrial KATP channel as a new target to control microglia
activity, avoid its toxic phenotype, and facilitate a positive disease outcome.
1. An Imbalanced Four-Partite
Synapse Crosstalk
Thediversity of clinical phenotypes of neurodegenerative dis-
eases share common neuropathological features that underlie
significant modifications of the physiological glia-neuronal
crosstalk. Over time, this leads to neuronal damage, spe-
cific pathway dysfunctions, and neurological disability [1].
Initially, the four-partite synapse, that is, the presynaptic
and postsynaptic neurons, astrocytes, andmicroglia, presents
a diversity of new communications that render and main-
tain a chronic neuroinflammation [1–3] with activation of
various well-coordinated adaptive mechanisms to avoid or
reverse damage [1, 3]. In fact, this imbalanced four-partite
synapse crosstalk underlies the disease pathogenesis, and its
progression—and also brain aging—reflects at each moment
the contributions of each cell type. Because of that, higher
perturbations are associated with significant molecular and
cellular changes that lead to a progressive chronic neu-
rodegenerative process from which return to physiological
conditions is impossible [4]. As such, the disease progression
represents the dynamic communicative process between all
the synaptic participants in which the equilibrium between
damaging and neuroprotective signals favors permanently
and increasingly neuronal damage and synaptic loss.
The pivotal role of these four cell types in disease has
yielded a huge amount of information to explain the dysfunc-
tion or disruption of neural circuits. At the present time, the
working theories attribute key roles to protein misfolding,
excitotoxicity, and mitochondrial dysfunction, this last one
related to integrity, bioenergetics, calcium homeostasis, or
reactive oxygen species (ROS) generation. In fact, all these
elements are interdependent, and all theories consider the
participation of the same four-partite synapse organization,
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in which microglia, as a sensor and effector of CNS immune
function, directly influence the disease initiation, progres-
sion, and outcome.
2. Microglia and Neurodegeneration
2.1. Misfolded Protein Diseases. Neurodegenerative diseases
can be classified asmisfolded protein diseases (MPD) because
each one presents specific misfolded proteins. These proteins
share no common sequence nor common structural identity
between them and include the Protease-resistant Prion Pro-
tein, Polyglutamine, Amyloid-𝛽, Tau protein, 𝛼-synuclein,
superoxide dismutase 1 (SOD1), TAR DNA-binding protein
43 (TDP-43), or fused in Sarcoma (FUS) [5, 6]. These
misfolded proteins reveal a failure to adopt a proper protein
folding due to an enhanced production of abnormal proteins
or to a perturbation of cellular function and aging under the
effects of ROS [7, 8]. In addition, their insufficient clearance
also reflects a chronic impairedmicroglia autophagy resulting
in accumulation of protein aggregates, cell damage, and
progressive death [1, 9]. For example, in amyotrophic lateral
sclerosis (ALS), the misfolded proteins like SOD1 released
initially from motor neurons activate microglia, and the
ensuing neuronal injury depends upon a well-orchestrated
dialogue between motor neurons and microglia [10]. Phago-
cytic microglial cells are very efficient scavengers but with
a limited capacity towards 𝛼-synuclein aggregates [11, 12]
characteristics for Lewy body disorders (LBDs), in particular
for Parkinson’s disease.The samemicroglia phagocytosis trig-
gers the release of proinflammatory cytokines, chemokines,
and ROS, which may further promote neuronal dysfunction
and degeneration and misfolded protein overload [13, 14].
In addition, microglia may also participate in the LBDs
pathophysiology due to variations of their human leukocyte
antigen region [15]. Thus, in all the different situations, the
protein aggregates initiate and maintain a chronic activation
of microglia as a constitutive element of MPD with their
subsequent direct participation in neural damage through
chronic ROS formation and cytokine secretion [16–18].
2.2. Excitotoxicity. Regarding excitotoxicity, the alterations of
synaptic glutamate and calcium homeostasis lead to neuronal
and glia glutamate receptor overactivation, culminating in
neuronal death and progressive neural circuit dysfunctions
[19, 20]. In this situation, threemain compensatory responses
are activated to avoid glutamate-induced damage [21]. Thus,
the direct activation of the retaliatory systems, based on
a coordinated increase of GABA, taurine, and adenosine
signaling, will reduce glutamate receptor activation [22, 23],
and the rapid adaptation of calcium homeostasis with the
neuronal and astroglial formation of calcium precipitates
will reduce the increased calcium signaling associated with
glutamate [3, 24], and the reduction of glutaminase activity of
the astrocyte-neuron glutamate/glutamine cycle will reduce
glutamate level in the presynaptic neuron and synaptic glu-
tamate activation [25]. Microglial cells are the glial cell type
least susceptible to excitotoxicity, because theymostly express
glutamate receptors when they are reactive. Injured neurons
would directly activatemicroglia [26] by the release of a diver-
sity of factors like galectin-3, [27], cystatin C, chemokine (C-
X3-Cmotif) ligand 1 (CX3CL1) [28], or the danger-associated
molecular pattern (DAMP) ligands that bind to Toll-like
receptors (TLR) [29]. The benefits of such inflammation
may be substantial to help avoid further neuronal damage
if exposure to excitotoxicity is limited in time or intensity
[25, 30]. Otherwhise, microglia effects will be deleterious
through chronic ROS formation and cytokines secretion and
directly related to the neurodegenerative process.With aging,
this process will be potentiated by the senescent affectation of
microglia, which changes cell morphology and functions [31–
33]. In fact, cumulative evidence indicates a direct pathogenic
role of senescentmicroglia in degenerative CNS diseases [34–
36].
2.3. Energy Demand and Microglia Reaction. Microglia do
not constitute a unique cell population but rather, present a
range of phenotypes [1, 37] closely related to the evolution
of the lesion process [33]. In a dynamic equilibrium with
the lesion microenvironment, these phenotypes range from
the well-known proinflammatory activation state to a neu-
rotrophic one directly involved in cell repair and extracellular
matrix remodeling [38], with a diversity of intermediary
mixed phenotypes that present or not a phagocytic activity
[39]. All these adaptative phenotypes relate directly to the
evolution of the lesion, and variations in the expression of
toxic, protective factors, and phagocytic activities greatly
determine the outcome of the tissue [33, 37, 40].
In addition, microglia-like neurons present a high-
energy demand, for which the lack of a mitochondrial DNA
(mtDNA) repair system determines mtDNA cumulative
defects with aging. As said previously, in these conditions,
senescent microglia become increasingly dysfunctional and
participates in the direct development of neurodegeneration
[40, 41]. As in other cells, calcium signaling governs the
communication between cytosol and mitochondria [42]. In
macrophages, the phagocytic response represents a burst
of ROS formation through an increased activity of the
NADPHoxidase and also ofmitochondria.Themitochondria
ROS (mtROS) are potentiated by the translocated tumor
necrosis factor receptor-associated factor 6 (TRAF6) [43]
and its interaction with the ubiquitinated protein evolu-
tionarily conserved signaling intermediate in Toll pathways
(ECSIT) [44]. ECSIT associates with the oxidative phospho-
rylation complex I components and facilitates the assembly
of the mitochondrial electron transport chain [44]. Thus, in
macrophages, TRAF6 translocation induces the juxtaposition
of phagosomes and mitochondria and potentiates mtROS
formation and energy production [45]. A similar TRAF6
recruitment to mitochondria that engages ESCIT on the
mitochondria surface is also observed in the same cells upon
lipopolysaccharide (LPS, a TLR4 agonist) treatment [43].
In microglia, recruitment of cytoplasmic TRAF6 modu-
lates LPS-evoked cytokine release [46]. The great similarity
between peripheral and central immune systems, in partic-
ular between macrophages and microglia, makes a similar
action of TRAF6 in microglia activated by LPS possible. If
true, the mitochondria respiratory burst rending increased
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energy and ROS production in response to the elevated
calcium required for the adoption of a specific microglia
phenotype would also depend on TRAF6 translocation and
interaction with ECSIT. And how calcium variations and
TRAF6 interact to modulate their microglia effects should
help identify the molecular pathways linked to the adoption
of a phenotype or another one.
In parallel, a defect in the astrocyte-neuron crosstalk
does not ensure sufficient neuronal supply of glucose, lactate,
and oxygen, leading to increased neuronal damage, probably
impossible to effectively repair [47]. This damage results in
subsequent switch in microglia phenotype from an initial
neuroprotective one to a final proinflammatory one and to
the disease onset and progression [1].
Thus, whether microglia adopt a phenotype that will
exacerbate tissue injury or one to promote brain repair and
phagocytosis is likely to depend on the diversity of signals
from the lesion environment and of the microglia response
capacity [48, 49]. At each moment, microglia effectiveness to
adapt to the changing synaptic signals and phagocytic needs
to rapidly remove cellular debris depends on its accurate
adaptation to match its immediate energy demand. This
implies that to ensure and maintain an activated stage and
adapt constantly their expression and function to a deter-
mined phenotype,microglia have to correspond permanently
with a balanced ATP availability from aerobic glycolysis [50].
However, like in astrocytes, in reactive microglia, part of
glucose rendersATP and lactate through anaerobic glycolysis.
Thus, in the postulated four-partite synapse, lactate will be
shuttling to neurons not only from astrocytes but also from
microglia.
Mitochondrial bioenergetics depends on a proper stim-
ulation of mitochondrial oxidative phosphorylation to pro-
duce enough ATP to the cell and on the same mitochondria
morphology [41, 51]. This requires a constant dynamic and
rapid response of its array of individual mitochondria to
adapt their shape and size to the microglia energy demand.
Thus, via the combined fusion and fission events that are
mediated by large guanosine triphosphatases, they improve
their number and optimize their regional networks in order
to deliver at each moment the needed ATP [52]. In microglia,
a higher number of mitochondria mark the transition from
microglia resting state to the activated one, as shown by
an increased expression of the mitochondrial peripheral
benzodiazepine receptor (PBR) labeled with (R)-PK11195
[53]. Both transmission electron microscopy (TEM) and
atomic force microscopy (AFM) procedures evidenced that
thismitochondrial PBR complex functions as a pore, allowing
the translocation of cholesterol and other molecules through
the inner mitochondrial membrane [54]. Presently, the (R)-
PK11195 ligand is commonly used to quantify microglia in
brain sections from excitotoxic damage like stroke, brain
trauma, epilepsy, or chronic neurodegenerative disorders [38,
55, 56] and also for PET detection as an in vivo marker of
active disease [57].
The mtDNA is arranged in nucleoprotein complexes
evenly distributed along the mitochondrial network [58].
Stimulation of mitochondrial fusion by mitofusin 1 and 2
and OPA1 maximizes oxidative phosphorylation because the
fused mitochondria share and homogenize the content of
all their compartments. Thus, when the mtDNA mutation
load is minor, integration of defective mitochondria through
fusion complementation increases their oxidative capacity by
sharing RNA components and proteins, because the lack of
a functional component in one mitochondria can be comple-
mented by the presence of the component in another one [59].
If the mutation load is major, fission activation by Drp1 and
Fis 1 increases the number of mitochondria and maintains
their physiological functions removing the defective parts
by mitophagy [60, 61]. Otherwise, abnormal mitochondrial
network dynamics develop, rendering dysfunctional cells as a
direct participant of the degenerative process. Presently, this
physiopathological mechanism has not yet been evidenced
in microglia. The known diseases associated with defects
in mitochondria fusion-fission factors, like the OPA1-linked
autosomal dominant optic atrophy, are genetic disorders,
and not specific of microglia [62]. However, the blockade of
glutamate-induced toxicity by antioxidants combined with
inhibitors of glutamate uptake argues for a key role of
ROS production in excitotoxicity [63]. Also, the impor-
tance of some inflammatory-independent neurodegenerative
mechanisms associated with mitochondria dysfunction and
oxidative stress in multiple sclerosis reinforces the possible
participation of defective microglia function in the disease
[64]. Thus, unraveling molecular mechanisms amenable to
prevent or reverse defective microglia mitochondrial net-
works would open new possibilities to control neurodegen-
erative disorders.
The rise in cytosol calcium signaling associated with
activation of glutamate and cytokine receptors of microglia
match microglia cell energy demand with mitochondria sup-
ply. Upon activation, microglia express glutamine synthase
(GS) and the two transporters EAAT-1 and -2 for glutamate
and glutamine synaptic extrusion [65]. In mitochondria,
glutamate and glutamine render oxoglutarate for the Krebs
cycle and ammonium. At high concentration, ammonium
contributes to the generation of superoxide, which after
reaction with NO forms the highly reactive peroxynitrite
[66]. The progressive reduction of neuronal glutaminase
activity that parallels the switch from the apoptotic to the
necrotic neuronal death [25] underlies a similar displacement
of the glutamate/glutamine cycle toward a reduced glutamate
formation and a net glutamine output [25]. So, the highest
glutamine level present in necrosis renders more ammonium
and more ROS production in microglia—adopting a mostly
proinflammatory phenotype—damaging the surrounding
cells and also their mitochondria network. This will cause
microglia dysfunctions that may result in apoptosis [66].
Finally, stimulation of the mitochondrial calcium uni-
porter (MCU), located in the inner membrane (MIM), pro-
motes an active mitochondria calcium uptake [67]. Calcium
moves down the MIM electrochemical gradient and, in
the matrix, stimulates the rate limiting enzymes—pyruvate,
isocitrate, and oxoglutarate dehydrogenases and also the
ATP synthase—to render increased amounts of ATP and
also of ROS [67–70]. Thus, whenever the cause of a major
energy demand, a defective protein that does not allow
a proper coordinated fission and fusion process induces
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a mitochondria dysfunction. This will cause a reduced
cytosol ATP availability, an increased ROS production, major
mtDNA dysfunctions, and a calcium dyshomeostasis, all of
them resulting in a definitive loss of mitochondria network
integrity and cell abnormalities [41, 71]. In view of the
abovementioned theories, which all consider the partici-
pation of cellular and molecular multidirectional synaptic
interactions, identification of therapeutic targets related to
disease pathogenesis for the rationale design of treatments
remains quite elusive. Modulation of microglia response
by controlling their mitochondrial activity constitutes an
innovative approach to interfere in the neurodegenerative
process. The identification of a mitochondrial KATP channel
expressed in human and rodents is a new target to control
microglia activity, avoid their toxic phenotype, and facilitate
a positive disease outcome.
3. KATP Channels in the CNS
KATP channels play important roles in many cellular func-
tions by coupling cell metabolism to electrical activity with
the participation of glucokinase. First detected in cardiac
myocytes, they have been found in pancreatic 𝛽 cells, skeletal
and smooth muscle, neurons, pituitary, and tubular cells of
the kidney [72–74]. In these tissues, KATP channels cou-
ple electrical activity to energy metabolism by regulating
potassium fluxes across the cell membrane when glucose
is available in sufficient conditions [75]. Increased energy
metabolism leads to channel closure, membrane depolariza-
tion, and electrical activity. Conversely, metabolic inhibition
opens KATP channels and suppresses electrical activity [76,
77].
Plasmalemmal KATP channels are assembled as a het-
erooctameric complex [78, 79] from two structurally distinct
subunits: the pore forming inwardly rectifying potassium
channel (Kir) subunit 6.1 or 6.2 and the regulatory sulpho-
nylurea receptor (SUR). SUR, like all other ATP-Binding
Cassette transporters, contains two transmembrane domains
and two cytoplasmic ones (Nucleotide Binding Folds 1 and 2).
Its N-terminal transmembrane domain mediates SUR-Kir6
interactions [80]. While ATP inhibits the KATP channel by
direct binding to the cytoplasmic Kir6 domains [81], acti-
vators like Mg-nucleotides [82] potassium channel openers
(KCOs) and inhibitors like sulfonylurea drugs [83] bind SUR
to modulate the channel. KATP channels play a multitude
of functional roles in the organism. In endocrine cells, they
play an important role in hormone release, including insulin
from pancreatic 𝛽 cells [84] and glucagon from pancreatic 𝛼
cells [85]. Epithelial cells of blood vessels also express KATP
channels, where they are involved in the control of blood flow
and cerebrovascular processes [86].
In the brain, neuronal expression of KATP has been
described in the substantia nigra, the neocortex, hippocam-
pus, and hypothalamus [72, 74]. In these areas, KATP channels
modulate electrical activity and neurotransmitter release
[87], protect against seizures [88], and play an essential role
in the control of glucose homeostasis [82]. The expression
of KATP channels has also been suggested in microglia [89].
As discussed in Section 4, our previous studies showed that
reactive microglia increase their expression of the KATP-
channel components Kir6.1, Kir6.2, SUR1, and SUR2B after
brain pathologies such as stroke and Alzheimer’s disease
(AD) [90–92].
Finally, KATP channels have also been described in the
mitochondria, located on the inner membrane of these
organelles where they play a crucial role in the maintenance
of mitochondrial homeostasis and of the proton gradient
involved in the respiratory chain [93, 94].
3.1. 𝐾
𝐴𝑇𝑃
Channel Gating and Pharmacology. The octameric
structure of the KATP channel with four inhibitory ATP-
binding sites per channel (one on each Kir6.2 subunit) and
eight stimulatory Mg-nucleotide-binding sites on SUR [95]
represents a complex regulation by nucleotides. The same for
the channel kinetics, with a large number of kinetic states, as
its activity reflects at eachmoment the result of the nucleotide
effects at each site. Several endogenous ligands bind the KATP
channel subunits: ATP (with or without Mg2+) inhibits the
Kir6.2 subunits, and phosphatidylinositol-4,5-bisphosphate
activates them; sulphonylureas inhibit the SUR subunits,
and KCO drugs activate them. In addition, in the presence
of Mg2+, ATP and ADP can activate the channel through
interaction with the nucleotide-binding folders of SUR [83].
Inhibition by ATP binding to Kir6.2 and activation by Mg-
nucleotides is probably the first physiological regulatory
mechanism [82].
In recent years, KATP channels have attracted increasing
interest as targets for drug development. Their pivotal role in
a plethora of physiological processes has been underscored
by recent discoveries linking potassium channel mutations
to various diseases. The second generation of KCOs or
potassium channel blockers, with an improved in vitro or
in vivo selectivity, has broadened the chemical diversity
of KATP channel ligands. However, despite this significant
progress, a lot of work remains to be done to fully exploit
the pharmacological potential of KATP channels and their
KCOs or potassium channel blocker ligands. Sulfonylureas
that bind KATP channel are oral hypoglycemic agents widely
used in the treatment of type II diabetes mellitus [96].
For example, glibenclamide binds with subnanomolar or
nanomolar affinity and is a potent inhibitor of SUR1-regulated
channel activity [97]. SUR1-regulated channels are exquisitely
sensitive to changes in themetabolic state of the cell, respond-
ing to physiologically meaningful changes in intracellular
ATP concentration by modulating channel open probability
[98].
On the other hand, considering the unique role that KATP
channels play in the maintenance of cellular homeostasis,
the KCOs family adds its potential in promoting cellular
protection under conditions ofmetabolic stress to the already
existing pharmacotherapy. Preclinical evidence indicates a
broad therapeutic potential for KCOs in hypertension, car-
diac ischemia, asthma, or urinary incontinence to mention
a few. For example, diazoxide (7-chloro-3-methyl-4H-1,2,4-
benzothiadiazine 1,1-dioxide) is a small molecule well known
to activate KATP channels in the smooth muscle of blood
vessels and pancreatic 𝛽 cells by increasing membrane per-
meability to potassium ions. Diazoxide binds with similar
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affinities to SUR1 and SUR2B on the interplay between SUR
and Kir subunits, a site different of the other KCOs binding
sites [83, 99], and its hyperpolarization of cell membranes
prevents calcium entry via voltage-gated calcium channels,
resulting in vasorelaxation and the inhibition of insulin
secretion [100]. For all this, diazoxide has been approved
and used since the 1970s for treating malignant hypertension
and hypoglycemia inmost European countries, the USA, and
Canada [101, 102].
4. The Mitochondrial KATP Channel
More than 20 years ago, a putative mitochondrial KATP
(mitoKATP) channel was proposed, both functionally and
molecularly distinct from the one in the plasma mem-
brane [103]. Initially, functional mitoKATP channels were
thought to be composed in brain of Kir6.1 or Kir6.2, and
SUR2B [104–106] and diazoxide or nicorandil have been
proposed as specific mitoKATP channel openers, whereas 5-
hydroxydecanoate would specifically block this channel type
[107–111].
Some authors have questioned the existence of the
mitoKATP channel since they failed to detect its existence
in isolated heart and brain mitochondria [112, 113], and the
specificity of diazoxide and 5-hydroxydecanoate has been
questioned [114, 115]. According to these authors, the lack
of specific effects of diazoxide could indicate that mitoKATP
channels are not present in mitochondria and that the phar-
macological effects of diazoxide and 5-hydroxydecanoate
are caused by interaction with other pharmacological or
unspecific targets (see [116] for a review). However, one must
consider that the variable findings can depend on minor
differences in mitochondrial isolation procedures, since the
channel may be inactivated during isolation ofmitochondria,
or a cofactor that needs to be present may be lost [113].
Moreover, the nonspecific effects of diazoxide are observed
in vitro when very high concentrations are used (higher than
50𝜇M). Since in rat heart mitochondria, diazoxide is found
to open mitochondrial KATP channels with a half-maximal
saturation of 2.3 𝜇M [94]. These concentrations are in excess
compared with those described to promote mitochondrial
KATP channel opening [117, 118].
Putative tissue heterogeneity ofmitoKATP channel expres-
sionmust also be taken into account to explain the specificity
of diazoxide actions. For instance, expression of KATP channel
components was not detected in resting microglia of rat
and human brain, whereas activated cells in ischemic rats
and AD patients presented strong labeling for SUR and Kir
components in the cytoplasm and plasmalemma [90–92]. In
this line, diazoxide prevents apoptosis of epithelial cells in
the aorta of diabetic rats compared to controls [119]. Thus,
in physiological conditions, very low expression of mitoKATP
channels in cardiac tissue or neurons may render cells
refractory to low diazoxide concentrations, whereas these
tissues may increase the channel expression in pathological
conditions.
Within this controversy, a major problem is that the
molecular identity of mitoKATP has not yet been determined.
A recent study has presented strong proteomic and phar-
macological evidence of kcnj1 as a pore-forming subunit of
mitoKATP channels [120]. This result supports the existence
of specific mitoKATP channels and should help to explain
the tissue specificity of different KCOs and clarify why some
authors found mitoKATP channels sensitive to drugs that do
not affect the plasmalemmal KATP one [121].
Because SUR1-regulated channels are exquisitely sensitive
to changes in themetabolic state of the cell and thatmicroglia
are permanently sensing the environment, the expression of
KATP channels in activated microglia will couple cell energy
to membrane potential and microglia response with the
adoption of a specific phenotype to the surrounding signals.
This channel expression may then be critical in determining,
at least in part, microglia participation in the pathogenic
process.
4.1. MitoK
𝐴𝑇𝑃
Channels in Neurodegeneration. Our labo-
ratory has described the expression of KATP channels in
microglia [1, 90, 91], which control the release of a diver-
sity of inflammatory mediators, such as nitric oxide (NO),
interleukine-6, or TNF-𝛼 [122]. In a rat model of neurode-
generation and in postmortem samples of patients with AD,
we also reported that activated microglia strongly expressed
KATP channel SUR components [90] and that reactive
microglia increase their expression of the KATP channel com-
ponents Kir6.1, Kir6.2, SUR1, and SUR2B after brain insults
[92, 122]. In this context, controlling the extent of microglial
activation may offer prospective clinical therapeutic benefits
for inflammation-related neurodegenerative disorders. We
and other authors have documented that pharmacological
activation of KATP channels can exert neuroprotective and
anti-inflammatory effects on the brain against ischemia,
trauma, and neurotoxicants [123–126].
Diazoxide has evidenced prevention of rotenone-
induced microglial activation and production of TNF-𝛼
and prostaglandin E2 in cultured BV2 microglia [126].
Also, diazoxide inhibited in vitro NO, TNF-𝛼, interleukin-6
production, and inducible nitric oxide synthase expression
by LPS-activated microglia. In mitochondria isolated from
these cells, diazoxide also alleviated rotenone-induced
mitochondrial membrane potential loss [126], for which
mitoKATP channels participate in the regulation of microglial
proinflammatory activation.
In vivo studies have confirmed that diazoxide exhibits
neuroprotective effects against rotenone, along with the
inhibition of microglial activation and neuroinflammation,
without affecting cyclooxygenase-2 expression and phago-
cytosis [126]. When tested in an experimental autoimmune
encephalomyelitis (EAE) murine model of multiple sclerosis,
1mg/kg oral diazoxide ameliorated EAE clinical signs but did
not prevent disease. A significant reduction in myelin and
axonal loss accompanied by a decrease in glial activation and
neuronal damage was observed. In this model, diazoxide did
not affect the number of infiltrating lymphocytes positive for
CD3 and CD20 in the spinal cord [122]. Finally, diazoxide
has been tested in the triple transgenic mouse model of
AD (3xTg-AD) that harbors three AD-related genetic loci:
human PS1M146V, human APPswe, and human tauP301L
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Figure 1: Effect of diazoxide treatment on the NMDA-induced hippocampal lesion. Microphotographs of Nissl-stained sections of a rat
hippocampus 15 days after the injection of 0.5 𝜇L of (a) vehicle, (b) 40mM NMDA, and (c) 40mM NMDA and treated with 1mg/kg/day
diazoxide p.o. Note that treatment with diazoxide decreased NMDA induced hippocampal lesion. (d) Isolectin B4 histochemistry (IB4)
staining of microglia in the hippocampus of sham rats, (e) NMDA-lesioned rats, and (f) NMDA rats treated with diazoxide. Note that
treatment with diazoxide decreased the area of enhanced IB4 staining. GFAP immunostaining of the astrocytes in the hippocampus of (g)
sham rats, NMDA-lesioned rats (h), and NMDA rats treated with diazoxide (i). Histograms show the quantification of the diazoxide effects
in the area of lesion (j), area of microgliosis (k), and area of astrogliosis (l) in the hippocampus of NMDA-lesioned rats. Sham refers to rats
injected with vehicle (50mM PBS, pH 7.4), NMDA refers to rats injected with 0.5 𝜇L of 40mMNMDA in the hippocampus, and NMDA +D
refers to NMDA-injected rats treated with 1mg/kg/day diazoxide p.o. from postlesion day 5 to 15. Stereotaxic coordinates were −3.3mm and
2.2mm from bregma and −2.9mm from dura [25]. All animals were manipulated in accordance with the European legislation (86/609/EEC),
𝑁 = 6 rats/group. Scale bar 1mm. ∗𝑃 < 0, 05 compared to sham, #𝑃 < 0, 05 compared to NMDA, LSD (posthoc test).
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
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Kir6.2 IB4 Merge
SUR1 IB4 Merge
Figure 2: Expression of KATP channel components SUR1 and Kir6.2 in activated IB4-positive cells into the core of the hippocampal lesion
(Bregma −3.3). ((a)–(f)) Confocal photomicrographs of hippocampal sections immunostained with IB4 and anti-Kir6.2 antibodies in control
((a)–(c)) and NMDA-lesioned rats ((d)–(f)). ((g)–(l)) Confocal photomicrographs of hippocampal sections immunostained with IB4 anti-
SUR1 antibodies in control ((g)–(i)) and NMDA-lesioned rats ((j)–(l)). Note that reactive amoeboid microglia stained with IB4 show specific
immunostaining with anti-Kir6.2 and anti-SUR1 antibodies in the cell membrane but also in the cytoplasm. For lesion details, see legend of
Figure 1. Scale bar 10𝜇m.
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Figure 3: Diazoxide modifies microglial reactivity in the brain. Drawing of the effects of mitochondrial KATP (mitoKATP) channel opening in
the energy metabolism and its consequences in the microglia reaction during neurodegeneration. (1) Diazoxide activates mitoKATP channels,
which (2) depolarizes the mitochondrial internal membrane (MIM), and (3) induces translocation of H+ by the electron transport chain
(ETC) that enhances both ATP synthesis and activation of the mitochondrial calcium uniporter (MCU) (4). Calcium in the mitochondria
activates dehydrogenases of the tricarboxylic acid cycle (TCA) (5) that also enhances ATP production (6). ATP closes the KATP channel from
the plasma membrane (7), while diazoxide opens the channel. As a result, the cell response to activation signals decreases (8), leading to a
reduction of the ROS generation and the inflammatory response (9) of reactive microglia (see the text for details).
[127], and 3xTgADmice treated with 10mg/kg/day diazoxide
for 8 months exhibited improved performance in the Morris
water maze test and decreased accumulation of A𝛽 oligomers
and hyperphosphorylated Tau in the cerebral cortex and
hippocampus [128]. In turn, exposition to A𝛽 oligomers
increases the neuronal expression of KATP channels. With
time, this increase is specific for Kir6.1 and SUR2 components
[129], which suggest that A𝛽 oligomers induce differential
regulations of KATP subunit neuronal expression. Exposed
to A𝛽 oligomers, the continuous oxidative stress results in
neuronal severe mitochondria dysfunction [130, 131], and the
expression changes of KATP channel components may reflect
neuronal attempts to resist the insult in accordance with the
metabolic state.
The chronic glutamate-mediated overexcitation of neu-
rons is a newer concept that has linked excitotoxicity to
neurodegenerative processes in ALS, Huntington’s disease,
AD, and Parkinson’s disease [19]. Such a chronic excitotoxic
process can be triggered by a dysfunction of glutamate
synapses, due to an anomaly at the presynaptic, postsynaptic,
or astroglial levels [21]. The contribution of excitotoxicity
to the neurodegenerative process can be reproduced by the
microinjection of low doses of glutamate agonist into the
rodent brain. Due to the high affinity of ionotropic glutamate
receptors for their specific agonists, such as N-methyl-D-
aspartate (NMDA), these drugs injected in non-saturable
conditions can trigger calcium-mediated excitotoxicity in
several rat brain areas and induce an ongoing neurodegen-
erative process [55, 56, 132, 133].
For example, anymicroinjection of NMDA in the rat hip-
pocampus triggers a persistent process that leads to progres-
sive hippocampal atrophy with a widespread neuronal loss
and a concomitant neuroinflammation [133]. This paradigm
alsomimics the alterations of other neurotransmitter systems
and neuromodulators found in human neurodegeneration
[22].
This neurodegenerative NMDA-induced hippocampal
process is also attenuated by diazoxide oral treatment, which
ameliorated microglia-mediated inflammation and reduced
neuronal loss (Figure 1). In this model, anti-SUR1 and anti-
Kir6.2 antibodies immunostained both the plasmalemma
membrane and the perinuclear space of amoeboid reactive
microglia (Figure 2), suggesting that microglial activation
involves expression and translocation of SUR1 from its inter-
nal reservoir toward the cell surface and the mitochondria.
Increased expression and translocation of the KATP channel
to the cell surface were also detected by specific binding of
fluorescently tagged glibenclamide (glibenclamide BODIPY
Oxidative Medicine and Cellular Longevity 9
FL; green fluorescence) to SUR1 in rat primary microglial
cultures [92].
Therefore, the expression of mitoKATP channels by acti-
vatedmicroglia indicates that KCOs, such as diazoxide, could
be used as therapeutic agents to treat inflammatory processes
of neurodegenerative diseases such as multiple sclerosis,
Parkinson’s disease, or AD.
4.2. MitoK
𝐴𝑇𝑃
Channels Modulate Microglia Reaction. As
explained, depending on the nature of the damage, microglial
activationmay take place, initially expressing neuroprotective
signals to help avoid further neuronal death, but then chang-
ing progressively to an inflammatory phenotype [33]. The
neuroprotective effects of diazoxide are proposed tomodulate
the inflammatory microglial activation, without affecting
cyclooxygenase-2 expression and phagocytosis [122, 126].
The mechanism of action of diazoxide and other KCOs has
not been completely elucidated yet. However, the diazoxide-
mediated neuroprotection is supposed to be mediated by its
interactions with mitochondria, which are the main ATP-
generating sites in microglial cells. In chronically reactive
microglia, diazoxide increases potassium flux into the mito-
chondrial matrix [117, 118] by activation of mitoKATP chan-
nels, which depolarize the MIM and preserve mitochondrial
structural and functional integrity [132]. Indeed, cells treated
with diazoxide demonstrate a favorable energetic profile with
limited damage following stress challenges [108, 134], and
mitoKATP channel opening promotes translocation of H
+
through the MIM, underscoring the protonophoric uncou-
pling and enhancing ATP synthesis (Figure 3). As a proposed
mechanism, mitoKATP channels opening serves to maintain
constant volume and avoid an excessive mitochondrial con-
traction that is deleterious for electron transport [117, 118].
Thus, mitoKATP channel opening may prevent respiratory
inhibition due to matrix contraction that would otherwise
occur during high rates of ATP synthesis. The increased H+
gradient also constitutes the energy source for calcium trans-
port through the MCU towards the mitochondrial matrix
[67]. This calcium controls the malate/aspartate transport
and dehydrogenases from the tricarboxylic acid cycle, which
finally results in increased production of NADH, the electron
donor of the respiratory chain. As a result, diazoxide increases
the ATP/ADP ratio in the mitochondria and cytoplasm
[135] of reactive microglia. ATP closes the KATP channels
from the plasma membrane preventing electrical activity
and modifying the cell response to tissue injury. However,
specific action of diazoxide on plasmalemma KATP channel
must not be discarded, and the activity of KATP channel in
the membrane will result from a compromise between the
ATP-mediated inhibition and the diazoxide-induced opening
(Figure 3). As a result, the cell response to tissue injury
includes a decreased synthesis of proinflammatorymolecules
and suppression of mitochondria-derived ROS [126] that
result in amaintenance of themitochondria network integrity
and of the phagocytic activity.
Thus, control of mitochondria activity by mitoKATP
channel opening decreases the microglia cytotoxic activity
and prevents overactivation of these cells during neurodegen-
eration. This therapeutic approach may keep the microglia
inflammatory activity under the cytotoxic threshold through-
out the course of the disease, avoiding amplification of the
progressive neuronal loss over time and facilitating a positive
disease outcome.
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